tbuckley/cabot-search huggingface dataset:
Roles and functions of a European Union Public Health Centre for Communicable Diseases and other threats to health
Authors: F Van Loock, N Gill, S Wallyn, A Nicoll, J C Desenclos, P Leinikki
Journal: Eurosurveillance (2002)

An international consensus has been reached that a European Union (EU) Technical Coordination Structure (TCS) for communicable diseases is needed to improve Europe s future response to international communicable disease threats within and beyond its boundaries. After the American events of September 11 2001 and the deliberate releases of anthrax, the EU created a Health Security Committee, adopted a civil protection decision, and established for 18 months a team to develop responses for deliberate releases of biological and chemical agents. These two initiatives, the network s approach and health security work, must converge into a single stream addressing health protection for the people of Europe. They could be combined into a European Centre for Communicable Diseases that is planned to become active by 2005.
Confounders in FDG-PET/CT Imaging of Suspected Prosthetic Valve Endocarditis
Authors: Asbjørn Mathias Scholtens, Laurens E. Swart, Hein Jan Verberne, Wilco Tanis, Marnix G.E.H. Lam, Ricardo P.J. Budde
Journal: JACC. Cardiovascular imaging (2016)
Effects of animal-assisted visits on quality of life during multi-modal radiation therapy: Chemotherapy regimens.
Authors: Stewart Barry Fleishman, Victoria Rosenwald, Peter Homel
Journal: Journal of Clinical Oncology (2013)

e20607 Background: Animal-assisted visits (AAV) are known to affect blood pressure, mood and anxiety, yet their effects in cancer remained unexamined. Methods: 42 subjects signed IRB-approved informed consent to have AAVs daily during multi-modal chemotherapy and radiation therapy for head &amp; neck cancer. 37 subjects completed at least baseline assessment visits for an intent to treat analysis. Assessments included FACT-Head and Neck scale; Satisfaction with AAV Intervention (SAAVI) assessing bi-weekly motivation to attend appointments, tolerance of waits, ability to withstand treatment, lingering effect of AAV after treatment and perception of social support. Subject characteristics: 25 (68%) male, mean age 57 years (57.22 ±8.44); (57%) white, 8 (22%) Hispanic, 6 (16%) black and 2 (5%) Asian. Cancer sites: oropharynx 23 (62%), hypopharynx 4 (11%), esophagus 3 (8%), laryngopharynx 2 (5%) and nasal cavity 2 (5%). Stage: stage II: 1 (3%), III: 6 (16%), IV: 30 (81%). All subjects received concomitant external beam radiation therapy with periodic cis-platin (23 pts, 57%), weekly carboplatin (7 pts; 16%) or cetuximab (5; 11%). Results: Comparing baseline, week 3 and week 7 assessments, FACT Physical Well-being (PWB; p&lt;0.001) and Functional Well-Being (FWB; (p=0.003) showed significant declines; in contrast, Social Well-Being (SWB; p = 0.03) showed significant gains. Controlling for declines in PWB, increases in EWB were also significant (p = 0.004). Satisfaction was measured after the first and last AAV. Mean scores for satisfaction related to psychological symptoms, generally liking animals/pets, and positive attitudes towards pets at both times were significantly better than “Neutral” or “Unsure” (all p &lt; 0.001), and did not change from first to last AAV. Mean scores for physical symptoms were not significantly different from “Neutral.” Conclusions: FACT analysis showed significant increase in EWB in the face of clinically evident and expected declines in PWB and FWB in spite of high symptom burden. The SAAVI assessment further supports the utility of the AAV intervention. Though self-selected for an affinity to pets and animals, subjects endorsed a high level of satisfaction with the intervention.
Vertebral Hemangiolymphangioma Mimics Bone Metastases on 99mTc-MDP SPECT/CT
Authors: Yiqiu Zhang, Beilei Li, Hongcheng Shi, Liang Cai, Jun Hou
Journal: Clinical Nuclear Medicine (2015)

Hemangiolymphangioma is a very rare, congenital malformation of both lymphatic and blood vessels. In the present study, we report a case of vertebral hemangiolymphangioma that was misdiagnosed as bone metastasis on 99mTc-MDP SPECT/CT.
Preparing to introduce the varicella vaccine into the Italian immunisation programme: varicella-related hospitalisations in Tuscany, 2004–2012
Authors: Sara Boccalini, Paolo Bonanni, Angela Bechini
Journal: Eurosurveillance (2016)

A universal immunisation programme against varicella in the form of the measles-mumps-rubella-varicella (MMRV) vaccine for toddlers aged 13–15 months was introduced in Tuscany in July 2008. An assessment of the impact of this programme on varicella-related hospitalisations 4 years after its introduction could further support its adoption at a national level. The hospitalisation data were analysed in two periods: pre-vaccination (2004–2007) and vaccination period (2009–2012). The high coverage of the vaccines (84% in 2012) resulted in a significant decline in notifications, from 33,114 (2004–2007) to 13,184 cases (2009–2012), and also of hospitalisations, from 584 (pre-vaccination period) to 325 (vaccination period). The hospitalisation rate was 4.1 per 100,000 (95% confidence intervals (CI): 3.4–4.7) before the introduction of vaccination, which dropped to 2.2 per 100,000 (95% CI: 1.7–2.7) in the vaccination period (hospitalisation risk ratios: 0.54; 95% CI: 0.472–0.619). The reduction was most significant in the youngest age groups. The introduction of universal vaccination has already led to a significant decline in hospitalisations due to varicella after just 4 years of implementation. Hospitalisation rates fell noticeably among younger individuals involved in the vaccination programme. The decrease in hospitalisation rate in the older age groups suggests a possible indirect protection.
Reply:
Authors: Gyongyi Szabo, Shashi Bala
Journal: Hepatology (2012)

We appreciate the feedback from the Sookoian group. Indeed, previous studies have demonstrated that plasma levels of miRNA-122 were increased in patients with nonalcoholic fatty liver disease (NAFLD).1 It was proposed by Pirola et al.2 that circulating miRNA-122, a marker of liver disease/damage, could also be used to predict the risk for cardiovascular disease in patients with NAFLD. A gene variant in the 3′ untranslated region of human L-arginine transporter SLC7A1, which is associated with hypertension, also contained an miRNA-122 binding site, and therefore the authors suggest that circulating miRNA-122 might be a bridge between metabolic signaling and cardiovascular disease. It is well known that miRNA-122 regulates a broad array of genes involved in fatty acid and cholesterol metabolism (e.g, FASN, ACLY, ACC, DGATS, AGPATS, HMGCR). Recent studies suggest that a deficiency of miRNA-122 in mice (germ line and hepatocyte-specific) results in hepatosteatosis, hepatitis, and hepatocellular carcinoma.3 Furthermore, miRNA-122 also regulates mitochondrial metabolism and tumor suppressor genes, and loss of miRNA-122 leads to hepatocellular carcinoma.3, 4 Given the multifactorial role of miRNA-122 in liver homeostasis, it might not be surprising that miRNA-122 could be a potential link between metabolic disorders and cardiovascular disease. Nevertheless, the notion that circulating miRNAs can modulate genes in a distant organ and/or mediate the disease has to be thoroughly investigated. To date, studies are very limited on the functional relevance of circulating miRNAs in vivo. Several principal questions still remain unanswered, such as the origin of circulating miRNAs (i.e., cells versus organs), their specificity, their in vivo biodistribution, and their turnover. Remarkably, a recent study demonstrated the induction of plasma miRNA-122 in an ischemic porcine cardiogenic shock model.5 It is most likely that liver ischemia triggered by cardiogenic shock resulted in the release of miRNA-122 to the circulation. However, this possibility was not explored. Further studies are warranted to examine the circulating miRNA in scenarios where multiple organs are affected. In conclusion, we cautiously support the hypothesis that circulating miRNAs may have paracrine effects extending to organs other than the organ of origin and thus the ability to modulate genes at distant organs. However, due to the lack of sufficient data on the functional relevance of circulating miRNAs, this remains a speculation at this time. Gyongyi Szabo M.D., Ph.D.*, Shashi Bala Ph.D.*, * Department of Medicine, University of Massachusetts Medical School, Worcester, MA.
Ultrasound/Magnetic Targeting with SPIO-DOX-Microbubble Complex for Image-Guided Drug Delivery in Brain Tumors
Authors: Ching-Hsiang Fan, Yu-Hang Cheng, Chien-Yu Ting, Yi-Ju Ho, Po-Hung Hsu, Hao-Li Liu, Chih-Kuang Yeh
Journal: Theranostics (2016)

One of the greatest challenges in the deployment of chemotherapeutic drugs against brain tumors is ensuring that sufficient drug concentrations reach the tumor, while minimizing drug accumulation at undesired sites.Recently, injection of therapeutic agents following blood-brain barrier (BBB) opening by focused ultrasound (FUS) with microbubbles (MBs) has been shown to enhance drug delivery in targeted brain regions.Nevertheless, the distribution and quantitative deposition of agents delivered to the brain are still hard to estimate.Based on our previous work on superparamagnetic iron oxide (SPIO)-loaded MBs, we present a novel theranostic complex of SPIO-Doxorubicin (DOX)-conjugated MB (SD-MB) for drug delivery to the brain.Magnetic labeling of the drug enables direct visualization via magnetic resonance imaging, and also facilitates magnetic targeting (MT) to actively enhance targeted deposition of the drug.In a rat glioma model, we demonstrated that FUS sonication can be used with SD-MBs to simultaneously facilitate BBB opening and allow dual ultrasound/magnetic targeting of chemotherapeutic agent (DOX) delivery.The accumulation of SD complex within brain tumors can be significantly enhanced by MT (25.7 fold of DOX, 7.6 fold of SPIO).The change in relaxation rate R2 (1/T2) within tumors was highly correlated with SD deposition as quantified by high performance liquid chromatography (R 2 = 0.93) and inductively coupled plasma-atomic emission spectroscopy (R 2 = 0.94), demonstrating real-time monitoring of DOX distribution.Our results suggest that SD-MBs can serve as multifunction agents to achieve advanced molecular theranostics.
Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection
Authors: Hee Chul Nam, Hae Lim Lee, Hyun Yang, Myeong Jun Song
Journal: Clinical and Molecular Hepatology (2016)

Background/Aims: The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV). We evaluated the efficacy and safety of DCV and ASV for HCV in real-life practice. Methods: Patients were treated with 60 mg of DCV once daily plus 200 mg of ASV twice daily for 24 weeks, and followed for 12 weeks. The primary endpoint was a sustained virological response at 12 weeks after treatment (SVR12) and safety. Results: This retrospective study included eight patients with chronic HCV genotype 1b infection. All of the enrolled patients were diagnosed with liver cirrhosis, and their mean age was 65.75 years. One patient was a nonresponder and two patients relapsed with previous pegylated interferon (PegIFN) and ribavirin (RBV) treatment. None of the patient showed NS5A mutation. An SVR12 was achieved in 88% of cases by the DCV and ASV combination therapy. The serum transaminase level and the aspartate-aminotransferase-to-platelet ratio were improved after the treatment. DCV and ASV were well tolerated in most of the patients, with treatment discontinuation due to adverse events (elevated liver enzyme and decompensation) occurring in two patients. Conclusion: In this study, combination of DCV and ASV treatment achieved a high sustained virological response with few adverse events even in those with cirrhosis, advanced age, and nonresponse/relapse to previous interferon-based therapy. Close monitoring of safety issues may be necessary when treating chronic HCV patients receiving DCV and ASV, especially in older patient and those with cirrhosis. Keywords: Hepatitis C virus; Liver cirrhosis; Direct-acting antivirals; Daclatasvir; Asunaprevir
Results of a French Survey on the Role of Tobacco, Particularly Inhalation, in Different Cancer Sites
Authors: Daniel Schwartz, Robert Flamant, Joseph Lellouch, Pierre F. Denoix
Journal: JNCI Journal of the National Cancer Institute (1961)

The results of a retrospective study of 3,937 cancer patients are presented, with controls matched by age and interviewer. A list of sites associated with smoking is established, including the lip, tongue, oral cavity, oropharynx, hypopharynx, larynx, lung, esophagus, and bladder. By considering the different criteria of consumption, we were able to separate these sites into two groups: (a) In cancer of the lip, oral cavity (excluding the tongue), oropharynx, hypopharynx, and esophagus, neither inhalation nor preference for cigarettes seems to be significant. (b) Inhalation and preference for cigarettes are significant for cancer of lung, larynx, and probably bladder. In the sites listed in (b), inhalation was an important factor, independent of the amount smoked or the method of smoking. The particular significance of the cigarette is less definite; it depends, in part, but in part only, on inhalation, which is associated with this type of smoking. To give a complete explanation of the significance of cigarettes, we have included other considerations: Smokers of the cigarette-only, pipe-only, and pipe-and-cigarette categories differ in certain respects and perhaps in their manner of smoking in general. The effect of inhalation appears, in this study, to be specific. Thus it is significant in some sites of cancer but not in others, and the study of a group of noncancerous patients brings out the relationship between inhalation and certain diseases.
PD2-3-6: ERBB3 expression correlates with vorinostat and gefitinib activity and its co-expression with E-cadherin restores response to gefitinib in NSCLC
Authors: Samir E. Witta, Fred R. Hirsch, Razvan Lapadat, Rafal Dziadziuszko, Paul A. Bunn
Journal: Journal of Thoracic Oncology (2007)
The Serum Spectrum Of Cytokines In Patients With NK/T-Cell Lymphoma and Its Cilincial Significance In Survival
Authors: Qichun Cai, Hui-qiang Huang, Bing Bai, Gao Yan, Jiang Li, Suxia Lin, Yi Xia, Xiaoxiao Wang, Jiabin Lu
Journal: Blood (2013)
Contribution of mercaptopurine dose intensification to improved outcome in patients with lower-risk ALL.
Authors: M Abromowitch, D Fairclough
Journal: Journal of Clinical Oncology (1990)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1990.8.8.1442 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2380762 Contribution of mercaptopurine dose intensification to improved outcome in patients with lower-risk ALL. M AbromowitchxM AbromowitchSearch for articles by this author , D FaircloughxD FaircloughSearch for articles by this author https://doi.org/10.1200/JCO.1990.8.8.1442 PDF "Contribution of mercaptopurine dose intensification to improved outcome in patients with lower-risk ALL.." Journal of Clinical Oncology, 8(8), pp. 1442–1443© 1990 by American Society of Clinical Oncology
New Closure for Radical Mastectomy Incisions
Authors: I R TRIMBLE
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patient surveillance after curative-intent treatment for ovarian cancer: What motivates clinicians?
Authors: Nimah Jamaluddin, Katherine S. Virgo, Feng Gao, David Gardner Mutch, Frank E. Johnson
Journal: Journal of Clinical Oncology (2012)

e15528 Background: In the US, ovarian cancer is diagnosed in &gt; 20,000 women and causes &gt;13,000 deaths each year. After curative-intent initial treatment, surveillance is common. Marked variation in surveillance intensity has been documented, suggesting overuse and/or underuse of resources. We sought to determine what factors motivate gynecologic oncologists as they design their surveillance strategies. Methods: A survey about ovarian cancer surveillance after initial treatment was mailed to all 943 members of the Society of Gynecologic Oncologists. The survey included 14 questions about putative motivating factors. Responses were submitted on a 10-level Likert scale. Motivating factors were ranked by the percent of responses for each of the ten levels. Results: 323 of the 943 (34%) responded; 283 responses were evaluable. “Current literature documents significant survival benefits” was the weakest motivating factor. Conclusions: The table below is consistent with the lack of evidence that any particular surveillance strategy confers any survival benefit. This is the first empirical evidence concerning factors that may motivate gynecologic oncologists in designing their surveillance strategies. Understanding motivating factors may be useful in devising methods to diminish the marked variation in strategies. [Table: see text]
A Critical Care Societies Collaborative Statement: Burnout Syndrome in Critical Care Health-care Professionals. A Call for Action
Authors: Marc Moss, Vicki S. Good, David Gozal, Ruth Kleinpell, Curtis N. Sessler
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Section:ChooseTop of pageAbstract <<ContentsWhat Is BOS?Prevalence of BOS in Crit...Risk Factors for BOSConsequences of BOSInterventions to Prevent ...A Call for ActionConclusionsReferencesCITING ARTICLES
Case 20-1984
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, Erwin F. Hirsch, Andrew E. Rosenberg
Journal: New England Journal of Medicine (1984)

Presentation of CaseA 27-year-old man was admitted to the hospital because of trauma.He was well until 19 hours earlier, when he was involved in a motor-vehicle accident. He was taken to another hospital, where multiple injuries were found. Abdominal examination showed tenderness in the midepigastrium and left lower quadrant, without other abnormality. The systolic blood pressure fell to the range of 70 to 90 mm Hg and improved after fluids were administered by vein. The urine was normal. The hematocrit was 46 per cent, and the white-cell count 19,800. The urea nitrogen was 13 mg per 100 ml . . .
Validation of DWI in assessment of radiotreated bone metastases in elderly patients
Authors: Alfonso Reginelli, Giustino Silvestro, Giovanni Fontanella, Angelo Sangiovanni, Mario Conte, Iolanda Nuzzo, Mariagrazia Calvanese, Marianna Traettino, Piera Ferraioli, Roberta Grassi, Roberto Manzo, Salvatore Cappabianca
Journal: International Journal of Surgery (2016)
Ectodermal dysplasia with immunodeficiency caused by a branch-point mutation in IKBKG/NEMO
Authors: Sofie E. Jørgensen, Pernille Bøttger, Emil Kofod-Olsen, Mette Holm, Nanna Mørk, Torben F. Ørntoft, Uffe B.S. Sørensen, Jens Magnus Bernth-Jensen, Troels Herlin, Jens Veirum, Carsten S. Larsen, Lars Østergaard, Rune Hartmann, Mette Christiansen, Trine H. Mogensen
Journal: Journal of Allergy and Clinical Immunology (2016)
Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with <i>de novo</i> or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL)
Authors: D. A. Thomas, H. M. Kantarjian, J. E. Cortes, F. Ravandi, S. Faderl, D. Jones, L. Letvak, R. E. Champlin, S. M. O'Brien
Journal: Journal of Clinical Oncology (2008)

7019 Background: Historically, complete remission (CR) rates with hyper-CVAD in de novo adult Ph-ALL were 90% or better; disease recurrence remained problematic. The selective ABL tyrosine kinase inhibitor (TKI) imatinib was thus incorporated into hyper-CVAD for de novo or minimally treated Ph-ALL. Methods: The final regimen included imatinib 600 mg days 1–14 of induction, 600 mg continuously with courses 2–8, 800 mg during 2 yrs of maintenance therapy interrupted by intensifications, followed by imatinib indefinitely. Allogeneic stem cell transplant (SCT) was performed in first CR as feasible. The study accrued from April 2001 to September 2006. Fifty-four pts with imatinib-naive de novo or minimally treated Ph-ALL were treated: 6 were refractory to 1 induction course and 9 were in CR at start. Median age was 51 yrs (17–84); 52% were male, and 13% had CNS disease. Results: 42 of 45 pts (93%) with active disease achieved CR (1 CRp, 1 PR, 1 early death). All 6 refractory pts achieved CR. Molecular CR rate (MCR, confirmed by nested PCR) was 52% overall. Outcome was similar for achievement MCR vs no MCR (prior to SCT) with 3-yr disease-free (DFS) and overall survival (OS) rates of 80% vs 60% and 62% vs 50%, respectively (p=NS). Sixteen pts (33%) underwent allogeneic SCT in first CR a median of 5 mos from start of therapy (1–13). In the de novo group, 14 pts with median age 37 yrs had SCT whereas 33 pts with median age 53 yrs did not. 2-yr OS rates were 70% vs 58%, respectively (p=0.09), with 4 deaths in CR (2 infection, 2 GVHD) after SCT versus 10 deaths in CR (7 infection, 1 pancreatitis, 1 CNS hemorrhage, 1 unknown) after chemotherapy. With median follow-up of 4 yrs (13–74 mos), 22% pts relapsed within median of 15 mos (8–42), including 2 after SCT without imatinib maintenance. In the de novo group, 3 of 8 evaluable relapses had non-T315I ABL kinase domain mutations. The addition of imatinib improved outcome compared with hyper-CVAD alone (irrespective of SCT); overall 3-yr DFS and OS rates were 62% vs 14% and 55% vs 15%, respectively, p<0.001. Conclusions: Incorporation of second generation TKIs into the hyper-CVAD regimen may further improve on the favorable imatinib experience. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Novartis Novartis Novartis Novartis
The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure
Authors: Aziz Nazha, Rami S Komrokji, Guillermo Garcia-Manero, John Barnard, Cassie Zimmerman, Al Ali Najla, Gail J. Roboz, David P. Steensma, Amy E. DeZern, Elias Jabbour, Sangmin Lee, Molly D. Greenberg, Alan F List, Hagop M. Kantarjian, Jaroslaw P. Maciejewski, Mikkael A. Sekeres
Journal: Blood (2014)
Comparison of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Extranodal NK/T-Cell Lymphoma, Nasal Type: Analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group
Authors: Ritsuro Suzuki, Shinichi Kako, Rie Hyo, Koji Izutsu, Toshiro Ito, Katsuji Shinagawa, Tomoyuki Endo, Hisashi Sakamaki, Junji Suzumiya
Journal: Blood (2011)